The researchers used genome-wide mapping to identify parental-origin effects affecting pig growth traits, then examined molecular variation using haplotype-resolved transcriptomes and epigenomes from reciprocal crosses. This approach distinguished parental alleles and allowed the investigators to compare their expression, epigenetic features and chromatin organization. The analysis also recapitulated established imprinting effects at loci such as IGF2 and KCNQ1, supporting the view that the method captured known genomic imprinting signals.

One group of signals involved rib length. The researchers linked distal POE loci for this trait with IGF2 through long-range chromatin interactions, indicating that physical contacts between distant genomic regions may contribute to the regulation of rib length. This is a genomic and chromatin association, not evidence that changing the interaction would necessarily alter the trait. The study therefore supports chromatin interactions as a possible contributor to parent-of-origin effects without establishing them as a proven causal mechanism.

The results further indicated that some POEs emerged from parent-specific three-dimensional chromatin architecture independently of allele-specific expression or histone marks. In these cases, parental differences appeared in the spatial organization of DNA even though the analyzed gene-expression and histone-based signals did not account for the effect. The authors identified chromatin topology as a plausible candidate mechanism of parental-origin regulation, while cross-species comparisons nominated additional candidate imprinted genes that require further validation. Together, the findings portray POEs as common and mechanistically diverse features of complex-trait inheritance in pigs.

Subject of Research: Genome-wide and haplotype-resolved analysis of parent-of-origin effects on growth traits in pigs

Article Title: Integrating genome-wide association study and haplotype-resolved epigenomes reveals complex parent-of-origin effects in pigs

Article References: Tao, L., Wang, L.-G., Li, J.-B., Zhang, S.-R., Zhang, L.-C., Deng, J.-K., Lin, J.-W., Hu, M., Adeola, A. C., Feng, X.-Y., Cen, D.-J., Huang, Z.-Q., Li, Q.-L., Liao, C.-Y., Yan, S.-S., Wang, L.-X., Xie, H.-B., & Zhang, Y.-P. (2026). Integrating genome-wide association study and haplotype-resolved epigenomes reveals complex parent-of-origin effects in pigs. BMC Genomics. https://doi.org/10.1186/s12864-026-13396-1

Image Credits: AI Generated

DOI: 10.1186/s12864-026-13396-1

Keywords: parent-of-origin effects, pigs, genomic imprinting, growth traits, epigenomics, chromatin interactions, three-dimensional chromatin, IGF2, KCNQ1, complex trait inheritance, Integrating, genome-wide

Genomic imprinting is orchestrated by epigenetic modifications, most notably DNA methylation, which are established during gametogenesis by the de novo methyltransferase DNMT3A and its cofactor DNMT3L, then maintained throughout life by DNMT1. Imprinted genes typically cluster within genomic loci governed by imprinting control regions, or ICRs, which display roughly fifty percent DNA methylation, reflecting parent-of-origin dependent regulation. Zinc finger proteins such as ZFP57 and ZNF445 tightly regulate the establishment of these methylation marks, and during early embryogenesis, when the epigenome is largely reset, ICRs are protected from demethylation by ZFP57 and the PGC7/STELLA complex. Histone modifications, including H3K9me3 and H3K27me3 on the silenced allele and H3K4me3 and H3K27ac on the active allele, reinforce this imbalanced expression pattern. Non-coding RNAs, such as the lncRNA AIRN, which silences the IGF2 receptor gene in mice, and insulator binding by CTCF, which coordinates expression across larger imprinted regions like the IGF2/H19 locus on chromosome 11p15.5, add further layers of regulation.

The most widely accepted evolutionary explanation for imprinting is the parental conflict hypothesis. Paternally expressed genes promote offspring growth during early development, while maternally expressed genes counterbalance this growth stimulation to preserve maternal health. This framework makes imprinting disruption particularly relevant to cancer, as many imprinted genes regulate cell growth, differentiation, and apoptosis. When imprinting is lost, either through reactivation of a normally silenced allele or silencing of a normally active allele, growth-promoting genes can become biallelically overexpressed while growth-limiting genes become completely silenced, directly fuelling tumorigenesis.

The clinical consequences of imprinting dysregulation extend well beyond cancer. Congenital syndromes such as Beckwith-Wiedemann, Prader-Willi, Angelman, Silver-Russell, Temple, and Kagami-Ogata all arise from disrupted imprinting at specific loci, often through DNA methylation defects, uniparental disomy, point mutations, or chromosomal aberrations. Beckwith-Wiedemann syndrome, characterised by excessive foetal growth and elevated childhood cancer risk, stems from dysregulated imprinting at the IGF2/H19 locus. Beyond congenital disorders, altered imprinting has been linked to cardiovascular conditions, including hypertension and atherosclerosis, where the DLK1-MEG3 domain is extensively hypomethylated in plaques, as well as neuropsychiatric disorders, with parent-of-origin effects implicated in autism spectrum disorder and schizophrenia.

In cancer, LOI at the IGF2/H19 locus is the most extensively documented imprinting alteration. Re-expression of the normally maternally silenced IGF2 allele and silencing of the maternally expressed H19 non-coding RNA are considered growth-promoting events. LOI at this locus has been detected in nearly thirty percent of colorectal cancer patients’ normal colonic mucosa, and its presence in blood greatly increases the odds of both colorectal adenoma and carcinoma. IGF2/H19 LOI has also been described in breast, liver, lung, and Wilms tumour, where it recapitulates foetal-program proliferation patterns and leads to poorer treatment response and adverse clinical outcomes, making it a putative predictive and prognostic biomarker. Other imprinted loci, including DLK1 in gliomas and neuroblastomas, PEG3 in gliomas, CDKN1C in several cancer types, HM13 in breast, kidney, and lung tumours, and MEST in breast, ovarian, and lung carcinomas, also undergo LOI or aberrant methylation in cancer.

Studying imprinting in humans presents formidable technical challenges. In model organisms like mice, imprinting can be characterised cost-efficiently by mating parents from different inbred lines and profiling the largely heterozygous progeny. However, imprinting is often species-specific, making human-specific experiments necessary for clinical studies. The retinoblastoma gene RB1, for instance, is imprinted in humans but not in mice, and attempts to generate an imprinted mouse model were unsuccessful. Similarly, the synteny of WT1 and IGF2 on chromosome 11p in humans, which allows a single complex genetic event to produce both aberrations in Wilms tumour, does not exist in mice, making murine models less representative of the human disease.

The gold standard for human imprinting research combines genomics and transcriptomics in a parent-offspring trio setting. By genotyping the offspring, heterozygous loci are identified, upon which RNA sequencing of the tissue under study reveals whether only a single allele is expressed. Comparison with parental genomics data then determines from which parent the expressed allele is inherited. However, this strategy is limited by the need for heterozygosity to discriminate between alleles, requiring sufficiently large numbers of trios and expensive designs combining both genomics and transcriptomics data. Case-control studies that first screen for candidate imprinted loci in controls, followed by analysis in cases, abolish the requirement for trio data but often lead to false positives, particularly due to allele-specific expression effects independent of parental origin, such as random monoallelic expression of human leukocyte antigen genes.

Epigenetics-based strategies, focusing on DNA methylation rather than expression, offer an alternative approach. Whole-genome bisulfite sequencing provides base-resolution DNA methylation profiling by converting unmethylated cytosines to uracil, allowing evaluation of whether methylation at ICRs deviates from the anticipated fifty percent. However, bisulfite treatment induces DNA degradation, and the requirement for large, high-quality, high-purity tumour samples poses significant challenges in cancer research. Enzymatic methylation sequencing (EM-seq) has emerged as a gentler alternative, while reduced representation bisulfite sequencing and targeted capture strategies reduce cost. DNA methylation arrays, particularly the Illumina Infinium MethylationEPIC platform, offer a cost-effective genome-scale option, though they lack allele-specific read-out, making it unclear whether methylation alterations reflect dysregulated imprinting or altered cell-type composition. Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA), which combines copy number and methylation assessment, remains the most widely used methodology for diagnosing imprinting syndromes.

Three major methodological challenges complicate the interpretation of imprinting analyses in cancer. First, most studies rely on bulk tumour samples that may contain substantial fractions of non-tumour cells, such as tumour-associated fibroblasts or infiltrating immune cells, reaching up to fifty percent in renal cancer. If admixing cell types feature different imprinting patterns, incorrect LOI calls may result. Second, the need for heterozygosity to discriminate paternal from maternal alleles means that the power to detect LOI varies across the genome as a function of genotype frequency, a major bottleneck for clinical assays. Third, transcript-specific imprinting, observed for loci such as MEST and IGF2, can lead to inconsistent LOI calls across a gene’s SNPs, while widespread copy number alterations in cancer can cause both false-positive LOI calls and genuine LOI events through deletion or gain of an originally silenced allele.

Emerging technologies promise to address these challenges. Single-cell RNA sequencing resolves tumour heterogeneity by profiling individual tumour cells, though many platforms miss the SNPs required to separate alleles, and single-cell data sparsity limits genome-wide character. Pseudobulk strategies, combining data from tumour cells or subpopulations, mitigate this resolution problem. Spatial transcriptomics and targeted methods like Quantitative Chromogenic Imprinted Gene In Situ Hybridization (QCIGISH) enable allele-specific visualisation even in homozygous backgrounds, addressing problems with tumour purity, copy number alterations, and heterozygosity. QCIGISH has been validated in cancer patient cohorts, achieving near-perfect sensitivity and specificity for early-stage lung cancer detection and enabling cervical cancer risk stratification. Long-read sequencing technologies offer the possibility to resolve transcript-level imprinting patterns and provide direct DNA methylation read-out during genome sequencing, avoiding bisulfite-related problems. The authors argue that integrating single-cell, spatial, and long-read strategies into multi-omics approaches will largely resolve remaining issues with non-cancer cells in bulk tissues and the need for heterozygosity and transcript-level resolution, ultimately guiding the development of optimised clinical tests and even epigenome-editing therapies for cancer.

Subject of Research: Genomic imprinting and its dysregulation in cancer

Article Title: Challenges and emerging strategies for genome-wide evaluation of loss of imprinting in cancer

Article References: Amin, M. T., Coussement, L., & De Meyer, T. (2026). Challenges and emerging strategies for genome-wide evaluation of loss of imprinting in cancer. British Journal of Biomedical Science, 83, Article 16709. https://doi.org/10.3389/bjbs.2026.16709

Image Credits: AI Generated

DOI: 10.3389/bjbs.2026.16709

Keywords: genomic imprinting, loss of imprinting, cancer, epigenetics, DNA methylation, biomarkers, single-cell sequencing, long-read sequencing, Challenges, emerging, strategies, genome-wide

Prader-Willi syndrome arises when imprinted genes on the paternal copy of chromosome 15, in a region called 15q11.2-q13, fail to function properly. Genomic imprinting means that for this stretch of DNA, only the father’s copy is supposed to be active; when it is missing or silenced, the result is a multisystem disorder affecting roughly 1 in 10,000 to 1 in 30,000 births. The clinical course unfolds in stages: newborns are floppy and struggle to feed, often needing tube feeding, while later in childhood the syndrome pivots to relentless overeating and progressive obesity, along with developmental delay, hormonal problems such as undescended testes and short stature, and distinctive facial features. There are four recognized molecular routes to the syndrome, with paternal deletion of the critical region accounting for 65 to 75 percent of cases and maternal uniparental disomy, in which a child inherits two maternal copies of chromosome 15 and no paternal copy, explaining another 20 to 30 percent.

G6PD deficiency is a different beast altogether. It is an X-linked condition caused by pathogenic variants in the G6PD gene, which encodes an enzyme that protects red blood cells from oxidative damage. More than 400 million people worldwide carry disease-associated variants, making it one of the most common enzymatic defects in humans, yet most carriers never experience a spontaneous hemolytic crisis. Trouble typically strikes only after exposure to triggers such as fava beans or certain oxidant medications, which can cause red blood cells to rupture. Because the gene sits on the X chromosome, hemizygous males, who possess only one X chromosome, are predominantly affected.

The three boys in the new report, all of Han Chinese descent and conceived without consanguinity, were diagnosed between August 2022 and December 2024. Each presented with the textbook hallmarks of Prader-Willi syndrome: severe neonatal hypotonia, feeding difficulties requiring hospitalization, cryptorchidism, slow weight gain, and growth retardation. Patient 1, diagnosed at two months of age, was born at full term by cesarean delivery weighing 2.45 kilograms; his mother had gestational diabetes and reported reduced fetal movement. Patient 2, diagnosed at one month, showed the classic PWS facial appearance, generalized hypopigmentation, and sticky saliva, and needed nasogastric feeding. Patient 3, born preterm at 37 weeks and weighing 2.2 kilograms, required prolonged tube feeding. Strikingly, none of the three showed any sign of G6PD-related illness: no jaundice, no anemia, no dark urine, and no hemolytic episodes across more than a year of follow-up.

The molecular workup tells the story of how both diagnoses were pinned down. Methylation-specific multiplex ligation-dependent probe amplification, or MS-MLPA, revealed abnormal methylation patterns at 15q11.2-q13 without any copy number change, pointing away from a deletion and toward uniparental disomy. Short tandem repeat analysis combined with trio whole-exome sequencing, in which the child and both parents are sequenced, confirmed that all three boys carried maternal uniparental disomy of chromosome 15. Patient 2 harbored a mixture of uniparental isodisomy, where two identical maternal copies are present, and heterodisomy, where two distinct maternal copies persist, while the other two carried simpler forms of maternal UPD. On the X chromosome, genetic testing uncovered maternally inherited hemizygous G6PD variants: one boy carried c.152C>T (p.Thr51Ile), classified as likely pathogenic under American College of Medical Genetics and Genomics criteria, and the other two carried c.1388G>A (p.Arg463His), a recognized mutation hotspot classified as pathogenic.

To place these cases in context, the team systematically searched five databases for literature published between 1956 and 2025, sifting through an initial pool of 4,908 citations to identify 28 well-documented patients with Prader-Willi syndrome plus an independent genetic disorder. These fell into two broad groups. Fourteen patients had sex chromosome abnormalities, including Klinefelter syndrome, trisomy X, 47,XYY syndrome, and mosaic Turner syndrome, with paternal deletion and maternal UPD subtypes represented roughly equally. Fifteen patients had autosomal conditions, which the authors subdivided by mechanism: chromosomal or genomic disorders such as Down syndrome, DiGeorge syndrome, and Sotos syndrome; autosomal recessive disorders unmasked by maternal UPD of chromosome 15; and monogenic disorders unrelated to chromosome 15, such as Pitt-Hopkins syndrome and ATP8A2-related cerebellar ataxia.

That mechanistic subdivision is where the biology gets genuinely interesting. When maternal uniparental disomy hands a child two identical copies of chromosome 15, any recessive pathogenic variant that the mother carries on that chromosome can suddenly be expressed in homozygous form. This so-called unmasking effect explains why nearly all reported autosomal recessive comorbidities, including Tay-Sachs disease, Bloom syndrome, congenital ichthyosis caused by CERS3 variants, hereditary spastic paraplegia type 11, isovaleric acidemia, and calpainopathy, arose in maternal UPD patients. The new G6PD cases extend this logic to the X chromosome: because the boys inherited their single mutant X from their mothers, the variant is hemizygous rather than homozygous, but the diagnostic principle is the same. A second, hidden pathogenic variant can ride along undetected unless clinicians actively look for it.

Why did the G6PD deficiency remain completely silent in these children? The authors propose that the developmental disruption caused by losing paternal imprinted gene expression on chromosome 15 is so profound that it dominates the clinical picture, overshadowing the milder biochemical consequences of X-linked hemizygous variants. Across the literature, the same pattern holds: in dual-diagnosis patients, the Prader-Willi phenotype tends to predominate, whether the second condition involves sex chromosome aneuploidy or autosomal variants. Notably, prior reports suggest that female maternal UPD patients can develop symptomatic X-linked disorders through skewed X-chromosome inactivation, adding another layer of complexity for future cases.

The clinical takeaway is arguably the most consequential part of the paper. Standard karyotyping and methylation testing cannot detect single-gene variants hiding elsewhere in the genome, and several previously reported children with maternal UPD-related recessive conditions showed no atypical features at initial diagnosis, with the second disease emerging only as they grew older. The authors argue that for any patient confirmed to have maternal uniparental disomy, trio whole-exome sequencing or even trio whole-genome sequencing deserves serious consideration, even when the phenotype looks entirely typical. Such expanded screening could catch maternally transmitted pathogenic variants on chromosome 15 and beyond, preventing missed dual diagnoses and allowing families to receive anticipatory guidance, such as the strict avoidance of fava beans and oxidant drugs that the parents of these three boys were counseled on.

Caveats remain. With only three patients, the series cannot establish whether the co-occurrence of maternal UPD Prader-Willi syndrome and G6PD deficiency reflects random chance, shared maternal geography or ancestry, or some deeper genetic predisposition, and the authors acknowledge the absence of quantitative G6PD enzyme activity testing in their cohort. Age-dependent features such as hyperphagia and scoliosis were not yet evaluable in children aged two to two and a half years, so longitudinal follow-up will be essential. Still, by expanding the recognized spectrum of Prader-Willi comorbidities and demonstrating that an X-linked condition can slip silently alongside an imprinting disorder, the study makes a compelling case that the era of multi-gene screening for imprinting disorders has arrived, and that the genome may hold more than one diagnosis for patients who appear to have just one.

Subject of Research: Co-occurrence of maternal uniparental disomy-type Prader-Willi syndrome and X-linked G6PD deficiency in three male infants

Article Title: Case Report: Concurrent maternal uniparental disomy-type Prader-Willi syndrome and X-linked G6PD deficiency—an area of focus on multi-gene screening for imprinting disorders

Article References: Zhou, Q., Yuan, J.-M., & Zou, C.-C. (2026). Case Report: Concurrent maternal uniparental disomy-type Prader-Willi syndrome and X-linked G6PD deficiency—an area of focus on multi-gene screening for imprinting disorders. Frontiers in Pediatrics, 14, Article 1924208. https://doi.org/10.3389/fped.2026.1924208

Image Credits: AI Generated

DOI: 10.3389/fped.2026.1924208

Keywords: Prader-Willi syndrome, G6PD deficiency, uniparental disomy, genomic imprinting, X-linked inheritance, trio whole-exome sequencing, MS-MLPA, genetic diagnosis, pediatric genetics, comorbid genetic disorders, ACMG variant classification, chromosome 15

The study’s scale is unprecedented for this age group. The team, led by researchers at the University of Cambridge and the University of Bergen, analysed age-standardised and sex-standardised BMI at eleven timepoints, from six weeks to eight years of age, in up to 62,276 children from the Norwegian Mother, Father and Child Cohort Study (MoBa). Across those timepoints they identified 369 genome-wide significant associations, which collapsed into 152 independent signals — a dramatic increase over the 25 loci found in the largest previous study of measured childhood BMI. Ninety-four percent of the 116 loci newly identified for BMI before age five had never been reported before, and none of the signals showed evidence of sex-specific effects.

A striking feature of the data is how much the genetic architecture of BMI changes with age. SNP-based heritability estimates rose after birth to a peak around the ‘adiposity peak’ at age one, then declined toward the ‘adiposity rebound’ around age five to six, mirroring the natural trajectory of body fat in early life. Genetic correlations told a similar story: the correlation between BMI in infancy and BMI in later childhood was only modest, at 0.39, and the correlation between childhood and adult BMI was lower still, at 0.19. In other words, the genetic variants that make a baby chubby are largely not the same ones that determine adult body size.

To push discovery further, the researchers used a statistical technique called genomic structural equation modelling to fuse three childhood-related traits into a single ‘childhood adiposity’ factor: BMI at age eight in MoBa, recalled comparative body size at age ten from 444,345 UK Biobank participants, and a genome-wide study of age at menarche, a trait tightly linked to early-life adiposity. This yielded an effective sample size of 599,924 individuals and 526 additional independent signals. A polygenic score built from the combined 624 signals explained up to 9.2 percent of variation in childhood BMI at age nine in the independent Avon Longitudinal Study of Parents and Children — outperforming scores based on adult BMI for every timepoint below age five.

When the team clustered the 624 signals by how their effects unfolded across childhood, two clear trajectories emerged. A ‘Transient’ group of 115 variants influenced BMI only during infancy, peaking between six weeks and about twelve months, while a ‘Persistent’ group of 507 variants continued to act into later childhood. The distinction matters clinically: in a disease-wide analysis of UK Biobank data, transient signals did not raise the risk of any adult disease and appeared mildly protective against type 2 diabetes and hypertension, whereas persistent signals raised cardiometabolic risk in ways that vanished once adult BMI was accounted for. The message is that infant fat that later resolves carries no long-term penalty — and may even confer benefit.

Gene-mapping analyses linked 434 high-confidence genes to the signals, and among them were eleven components of the leptin–melanocortin pathway, the master neuroendocrine circuit of appetite regulation whose disruption causes severe early-onset obesity. Signals tied to BSX, GNAS, LEPR and PCSK1 showed childhood-specific effects, while incretin pathway genes — GLP1R and GIPR, the very receptors targeted by today’s blockbuster weight-loss drugs — also emerged with effects confined largely to childhood. Notably, none of the GLP1R signals was associated with BMI beyond early childhood, and one PCSK1 variant even showed opposite effects on BMI in infancy and adulthood. Because the authors found that rare variants in these same pathways act more strongly in children than in adults, they suggest that drugs targeting the leptin–melanocortin pathway, such as leptin and setmelanotide, may be more effective in children than in adults.

Single-nucleus RNA sequencing data from the human hypothalamus added a neurobiological dimension. Childhood adiposity signals were enriched in 260 of 452 mapped hypothalamic cell populations, all of them neuronal — and nineteen of these were enriched only for childhood, not adult, signals. Five of the child-specific populations sit in the arcuate nucleus, the hypothalamic hub of energy homeostasis, and another five in the mammillary bodies, a region better known for memory. These cell populations were marked by expression of leptin–melanocortin and incretin components such as LEPR, POMC, MC4R, GLP1R and GIPR, hinting at brain circuits that regulate body fat specifically during development.

Whole-genome sequencing of 479,615 UK Biobank participants then extended the search to rare variants. Burden tests implicated six genes — ADCY3, CALCR, MC4R, MRAP2, POMC and MYH13 — with rare protein-coding variants that showed stronger associations with recalled childhood adiposity than with adult BMI. Four of the six encode central components of the leptin–melanocortin pathway, and the associations for ADCY3 and MRAP2 provided the first population-scale evidence that single copies of damaging variants in these severe-obesity genes measurably shift childhood body size. A novel association at MYH13, a muscle gene, affected childhood adiposity but showed no link to adult BMI at all.

The Norwegian cohort’s parent–child trios also allowed the team to probe genomic imprinting — the parent-of-origin silencing of certain genes. Evidence of imprinting emerged at signals near known imprinted regions, including a maternal effect at KLF14 on infancy BMI that reverses direction in adulthood, a childhood-specific paternal effect at GNAS, and a novel paternal-only association near ZDBF2, a gene that in mice regulates neonatal feeding and growth. The authors argue that these findings extend the classic parental-conflict hypothesis of imprinting, which was developed for fetal growth and puberty timing, to the regulation of childhood adiposity itself.

The study has limitations the authors acknowledge: the cohorts were of northern European ancestry, BMI in infancy is an imperfect proxy for fat mass, and the hypothalamic cell atlas was built from adult autopsy tissue. Larger, more diverse studies with directly measured infant body composition will be needed. Even so, the conclusion is hard to escape. With 624 signals — comparable to the 941 found for adult BMI in more than 700,000 people — childhood adiposity genetics proved at least as informative as its adult counterpart, and far more revealing about core energy-balance biology. As the authors put it, childhood appears to be a more sensitive window for detecting variation in the key endocrine and neuropeptide pathways that regulate how our bodies store fat, a finding that could reshape both obesity drug development and early-life prevention strategies.

Subject of Research: Genome-wide association and sequencing analysis of common and rare genetic variants influencing adiposity across childhood

Article Title: Genome-wide mapping of common and rare variant effects on adiposity across childhood

Article References: Kentistou, K. A., Sundfjord, J., Karimi, R., Kaisinger, L. R., Hofmeister, R. J., Fragoso-Bargas, N., Lupu, A. E., Zhao, Y., Tadross, J. A., Steuernagel, L., Dowsett, G. K. C., Lockhart, S., Brüning, J. C., Liu, J., Cortes, A., Lo, Y., Davitte, J., Clement, L., Havdahl, A., … Johansson, S. (2026). Genome-wide mapping of common and rare variant effects on adiposity across childhood. Nature Genetics. https://doi.org/10.1038/s41588-026-02772-y

Image Credits: AI Generated

DOI: 10.1038/s41588-026-02772-y

Keywords: childhood obesity, genome-wide association study, adiposity, leptin-melanocortin pathway, incretin signaling, hypothalamus, rare variants, genomic imprinting, polygenic scores, MoBa cohort, UK Biobank, BMI trajectories

Imprint control regions, or ICRs, are stretches of DNA carrying methylation marks that are laid down before gastrulation, very early in embryonic development, and then faithfully copied through every subsequent cell division. Because one parental allele is methylated while the other remains unmethylated, imprinted genes are expressed from a single copy, making them exquisitely sensitive gene dosage regulators. When these marks are disturbed, the consequences can be severe: imprinting abnormalities underlie Prader-Willi and Angelman syndromes, Silver-Russell and Kagami-Ogata syndromes, a range of cancers, neurological disorders, and chronic diseases linked to environmental contaminants. Because the marks are stable across tissues and across the life course, they also act as long-term molecular records of early-life exposures that questionnaires and conventional exposure assessments cannot recover.

The motivation for the new array stems from a 2022 study in which Dereje Jima and colleagues used whole-genome bisulfite sequencing, or WGBS, to map 1,488 candidate differentially methylated ICRs across the human genome. Before that work, only 24 human ICRs had been well characterized. WGBS remains the reference method because it can, in principle, read every CpG site in the genome, including all 22,157 CpG positions that fall within the newly catalogued ICRs. But it is expensive, demands high sequencing coverage, requires substantial computational infrastructure, and is impractical for the large sample numbers that epidemiological studies of chronic disease require. Existing targeted alternatives are similarly limited: pyrosequencing handles only short single sequences, pooled amplicon sequencing works only for small preselected target sets, and hybridization capture approaches such as targeted methyl-seq demand specialized instrumentation and expertise.

Commercial arrays offered no better solution. The Infinium Methylation EPIC v1 BeadChip covers just 1.4 percent of the CpG sites in the candidate ICRs, representing only 156 of the 1,488 regions with an average of two probes each. The newer EPIC v2 array improves on that, reaching 6.8 percent of the sites and 548 ICRs, but still leaves most of the imprintome unmeasured. To close this gap, the research team, led by Natalia Carreras-Gallo and Ryan Smith of TruDiagnostic together with Cathrine Hoyo, David Skaar, Randy Jirtle and colleagues at North Carolina State University and other institutions, extracted the 22,157 ICR-mapped CpG sites from the hg38 reference genome and worked with Illumina to design probes against them, applying the company’s validated quality thresholds for sequence, GC content and annealing temperature.

The resulting Human Imprintome array carries 22,819 probes in total, including 704 control probes and 22,115 CG probes. Of the CG probes, 10,438 target unique CpG sites, and 9,757 of those align successfully within the candidate ICR catalogue, covering 1,088 of the 1,488 regions, or 73.1 percent, with an average of nine probes per region and a maximum of 171. The design also retains 10,364 background-normalization probes and 1,313 multimapping probes, which were kept because they represent many ICRs but flagged with zeroed coordinates to prevent misassignment. Coverage remains sparse for ICRs on chromosomes 1 through 5 and chromosome 21, where repetitive sequence produces the most multimapping probes, and roughly 400 ICRs currently lack representation altogether, a limitation the team says it is already working to fix in a next version.

Validation proceeded along two fronts. First, the researchers processed matched samples on both the Human Imprintome array and the EPIC v2 array, using whole blood samples from an Alzheimer’s disease cohort recruited at the Duke Memory Clinic. Across 1,703 overlapping probe sites, Pearson correlation coefficients between the two platforms reached 0.788, 0.811 and 0.789 in the three samples tested, with a mean R-squared of 0.796. Notably, the beta-value distributions told a mechanistically satisfying story: while the full probe set of the Imprintome array showed peaks at methylation values of zero, one half and one, the subset of probes mapped to ICRs collapsed to a single dominant peak at one half, exactly the signature expected of parent-of-origin methylation in which one allele is fully methylated and the other fully unmethylated.

Second, the team compared the array against WGBS, the current gold standard, using sixteen autopsy brain specimens from the Duke/UNC Alzheimer’s Disease Research Center brain bank, comprising equal numbers of Alzheimer’s cases and controls among non-Hispanic Black and non-Hispanic White donors. Samples were pooled within each of four groups to boost sequencing coverage, which ranged from 10X to 15X with bisulfite conversion above 97 percent. After filtering CpG sites with fewer than ten sequencing reads, correlations between array and sequencing measurements ranged from 0.532 to 0.657, with a mean R-squared of 0.569. The authors attribute the lower agreement relative to the EPIC v2 comparison to the modest WGBS coverage and to fundamental differences between array-based and sequencing-based methylation measurement, rather than to any flaw in the array itself.

Reliability testing reinforced the platform’s credentials. Eight umbilical cord blood samples from the Newborn Epigenetics Study, a prospective birth cohort of 2,681 pregnant women recruited in Durham, North Carolina between 2005 and 2011, and seventeen whole blood samples from the Alzheimer’s cohort were each run twice on the Imprintome array. Intraclass correlation coefficients between replicate runs ranged from 0.799 to 0.945, with a mean of 0.868, indicating that the array delivers highly reproducible measurements, a prerequisite for biomarker development and for multi-center studies where batch effects and platform drift can otherwise swamp true biological signals.

The practical advantages of the new tool extend beyond coverage. Because it is built on the familiar Infinium BeadChip platform, it slots into existing laboratory workflows, from bisulfite conversion of 200 nanograms of DNA through hybridization on the iScan imaging system, and into established bioinformatic pipelines, including the sesame R package, which the authors used for preprocessing and which supports custom array manifests. Arrays are faster, cheaper and more automatable than next-generation sequencing for the targeted question of ICR methylation, and by concentrating probes on regions of interest, a custom array avoids paying for genome-wide content irrelevant to the research question. The team has also released comprehensive annotations of every probe and its ICR assignments, and plans to make data and resources available through the humanicr.org website.

The broader promise is considerable. With environmental and lifestyle factors estimated to account for 70 to 90 percent of the burden of common chronic diseases, yet with disease often emerging decades after exposure, stable early-established epigenetic marks are among the few measurable archives of developmental history the human body keeps. A reliable, scalable readout of the imprintome could accelerate the discovery of ICRs associated with cancer, neurological disease, imprinting syndromes and environmentally driven illness, sharpen causal inference in exposure epidemiology, and guide therapeutic strategies aimed at growth regulation and developmental disorders. For a field that until recently could name only two dozen human imprint control regions, the arrival of a dedicated, validated array marks a decisive step toward making the full imprintome a routine object of study rather than a specialized pursuit.

Subject of Research: Development and validation of a custom Infinium DNA methylation array for profiling human imprint control regions

Article Title: Creation and validation of the first infinium DNA methylation array for the human imprintome

Article References: Carreras-Gallo, N., Dwaraka, V. B., Jima, D. D., Skaar, D. A., Mendez, T. L., Planchart, A., Zhou, W., Jirtle, R. L., Smith, R., & Hoyo, C. (2024). Creation and validation of the first infinium DNA methylation array for the human imprintome. Epigenetics Communications, 4(1), Article 5. https://doi.org/10.1186/s43682-024-00028-6

Image Credits: AI Generated

DOI: 10.1186/s43682-024-00028-6

Keywords: genomic imprinting, imprintome, imprint control regions, DNA methylation, Infinium array, methylation array, epigenetics, whole-genome bisulfite sequencing, EPIC v2, custom BeadChip, environmental epigenetics, Alzheimer's disease

The study, published in the journal Genome Biology, was led by Junpeng Shi of Sun Yat-sen University together with colleagues at Shandong Agricultural University, the Chinese Academy of Sciences and other institutions. The endosperm, the triploid tissue that nourishes the developing embryo and ultimately makes up most of what we eat when we consume corn, has long been recognized as the primary arena for genomic imprinting in plants. Because it contains two maternal genome copies and one paternal copy, the endosperm provides a natural system in which researchers can distinguish whether a gene’s transcripts came from the mother or the father, simply by counting the relative abundance of parental alleles.

Previous efforts to catalog imprinted genes in maize relied on bulk RNA sequencing of endosperm tissue that had been painstakingly dissected by hand. Those studies identified hundreds of candidate imprinted genes, but they averaged expression signals across an entire tissue that is anything but uniform. The endosperm is a mosaic of specialized cell types, each with distinct developmental roles, and averaging across them risks blurring the very signals that matter. The new work set out to resolve that heterogeneity directly, asking whether imprinting looks the same in every endosperm cell or whether it, too, is compartmentalized.

To answer that question, the researchers deployed two complementary technologies. The first was 10x Visium spatial transcriptomics, which captures gene expression while preserving information about where in the tissue each transcript was detected. The second was single-nucleus RNA sequencing, or snRNA-seq, which profiles the transcriptomes of individual nuclei, allowing each cell’s identity to be inferred from its expression signature. Crucially, the team applied both methods to reciprocal maize kernels, meaning kernels produced by crossing two inbred lines in both directions, so that the maternal and paternal genomes could be swapped and parental origin of each allele tracked unambiguously.

The combined datasets revealed six major endosperm cell types, providing the most granular cellular atlas of this tissue to date. When the researchers examined allele-specific expression, the pattern of transcripts attributable to one parent versus the other, they found something striking: this expression was strongly cell-type specific. Roughly two-thirds of the genes showing allele-specific expression were detected in only a single endosperm cell type. In other words, the parental bias governing a gene’s activity is not a fixed property of the gene itself but depends heavily on which cellular neighborhood that gene happens to be operating in.

The two technologies proved highly consistent with one another. Nearly 70 percent of the imprinted genes identified through spatial profiling could be validated at the cell-type level using single-nucleus sequencing, a concordance rate that strengthens confidence in both platforms and in the biological conclusions drawn from them. Yet when the team compared imprinted gene sets across the different endosperm cell types, they found that fewer than half of the imprinted genes were shared among multiple cell types. The implication is profound: the imprinting landscape of the endosperm is substantially shaped by spatial position and cellular identity, not merely by the epigenetic state inherited from the gametes.

The study also addressed a long-standing question about the balance of parental influence. In maize endosperm, paternally expressed genes, those that preferentially silence the maternal copy and express the paternal one, outnumbered maternally expressed genes by approximately twofold. This asymmetry adds to evidence that the paternal genome exerts a stronger transcriptional imprint on endosperm development than the maternal genome, at least in terms of the number of genes affected, though the functional consequences of that imbalance remain an open question for future work.

Among the most intriguing discoveries was a maternally expressed long non-coding RNA located within a region of the genome where the maternal copy is hypomethylated, meaning it carries fewer DNA methylation marks than the paternal copy. This lncRNA sits alongside Mez1, one of the canonical, best-characterized imprinted genes in maize, which is known to reside in a differentially methylated region. The co-localization of a novel imprinted non-coding RNA with a classic imprinted protein-coding gene in a shared hypomethylated landscape suggests that these loci may be subject to coordinated epigenetic regulation, hinting at regulatory architectures that earlier bulk approaches simply could not see.

Technically, the work demonstrates how modern genomics can dissect a phenomenon that has resisted fine-scale analysis for decades. Allele-specific expression analysis requires distinguishing transcripts from two highly similar genome copies, and doing so in spatially resolved or single-cell data adds layers of computational complexity, from assigning nuclei to cell types to correcting for the uneven coverage typical of single-cell libraries. By validating spatial results against single-nucleus data, and by using reciprocal crosses to control for the effects of the specific inbred lines, the team built a methodologically robust framework that other plant researchers can now adapt to their own systems.

The broader significance of the study lies in what it says about the developmental logic of imprinting. The authors conclude that post-fertilization endosperm differentiation, the process by which the initially uniform triploid tissue diversifies into specialized cell types, actively shapes the spatial and cellular landscape of genomic imprinting in maize. Rather than being a static epigenetic legacy of fertilization, imprinting emerges as a dynamic, context-dependent program that unfolds as the kernel develops. The comprehensive resource generated by the team, including cell-type atlases, allele-specific expression catalogs, DNA methylation data and lncRNA annotations, is expected to serve as a foundation for investigating the functional roles of imprinting during kernel development, work that could ultimately inform efforts to improve seed traits in one of the world’s most important crops.

Subject of Research: Cell-type-resolved mapping of genomic imprinting and allele-specific expression in developing maize endosperm using spatial transcriptomics and single-nucleus RNA sequencing

Article Title: Spatial and single-nucleus transcriptomics reveal the complexity of genomic imprinting in maize

Article References: Li, T., Jiang, Y., Zhang, M., Zhu, K., Jiang, S., Yang, X., Liu, H., Wang, J., Dong, X., & Shi, J. (2026). Spatial and single-nucleus transcriptomics reveal the complexity of genomic imprinting in maize. Genome Biology. https://doi.org/10.1186/s13059-026-04291-9

Image Credits: AI Generated

DOI: 10.1186/s13059-026-04291-9

Keywords: maize, genomic imprinting, spatial transcriptomics, single-nucleus RNA sequencing, allele-specific expression, endosperm, epigenetics, DNA methylation, long non-coding RNA, Mez1, plant genetics, seed development

Imprinted genes are a peculiar subset of the genome. Most genes are expressed from both the maternal and paternal copies, but imprinted genes carry chemical tags laid down in the egg or sperm that silence one copy entirely, leaving only the maternal or paternal version active. In the placenta, these parent-of-origin effects are thought to reflect evolutionary conflict: paternal genes tend to push for greater extraction of maternal resources, while maternal genes restrain fetal demands to preserve the mother’s ability to sustain current and future pregnancies. Phlda2, formally known as Pleckstrin Homology-Like Domain Family A Member 2, is one of the maternal army’s foot soldiers, normally expressed only from the chromosome inherited from the mother.

Researchers at Cardiff University, led by R. M. John together with colleagues including A. R. Isles, had previously shown that elevated Phlda2 expression, a state mimicking loss of imprinting in which the gene’s dosage is effectively doubled, produces placentas that secrete fewer hormones, fetuses that grow poorly, and mothers that neglect their pups after birth. Their earlier work on the paternally expressed gene Peg3 had already demonstrated that imprinted genes can act as master regulators of placental endocrine lineages and that disrupting them can produce sexually dimorphic outcomes, with males suffering more. The natural question was whether a maternally expressed gene would show the same pattern, or whether the sexes would flip.

To find out, the team crossed wildtype C57BL/6 female mice with transgenic males carrying an extra bacterial artificial chromosome copy of Phlda2, generating embryos that overexpressed the gene and thus modelled loss of imprinting. They then dissected the placenta at embryonic day 14.5, a critical window when the placenta’s endocrine machinery is being established, and collected fetal and placental weights at embryonic day 18.5, near the end of gestation.

The team used RNAscope, a high-resolution in situ hybridization technique, combined with classical histology to map the placenta’s specialized cell populations. The mouse placenta is organized into two major compartments. The labyrinth zone handles nutrient and gas exchange, while the junctional zone is the endocrine heart of the organ, packed with hormone-producing cells including the spongiotrophoblast layer, glycogen cells, and parietal trophoblast giant cells. The spongiotrophoblast in particular churns out a vast repertoire of prolactin-related hormones and pregnancy-specific glycoproteins that remodel the mother’s physiology, directing blood flow, nutrient mobilization, and even priming her brain for maternal care.

What the researchers saw was unambiguous. In placentas carrying the Phlda2 overexpression, the junctional zone lost a significant number of spongiotrophoblast cells, and the depletion was substantially more severe in female placentas than in male ones. Glycogen cells and parietal trophoblast giant cells were also reduced in number, but those losses were even-handed between the sexes. The sexual dimorphism was confined specifically to the spongiotrophoblast compartment, the very cell population responsible for the placenta’s most powerful endocrine output.

Molecular measurements backed up the cellular picture. Using reverse-transcription quantitative PCR and bulk RNA sequencing, the team found that genes encoding placental hormones normally produced by the spongiotrophoblast were downregulated in the mutant placentas, and once again the reduction was biased toward females. Gene set enrichment analysis reinforced the conclusion: the female mutant placenta showed a more profound dampening of its hormone-producing program than the male, despite both sexes carrying the identical genetic modification.

The most consequential result, however, appeared in the growth curves. At embryonic day 18.5, late in gestation, female fetuses with elevated Phlda2 expression were significantly growth restricted compared with their wildtype female littermates. Male fetuses carrying the same transgene showed no comparable reduction in weight. In other words, the genetic perturbation narrowed the female placenta’s endocrine signalling capacity, and the female fetus paid the price by growing more slowly, while the male fetus maintained its growth trajectory despite the same molecular insult.

The authors interpret this asymmetry through the lens of evolutionary theory about parental resource allocation. Phlda2 is known to be responsive to maternal adversity: when the mother experiences nutritional deficiency or other forms of prenatal stress, placental Phlda2 expression rises, and the resulting restraint on hormone production lowers the fetus’s demands on her body. The new findings suggest that this demand-dampening system is not symmetrical. Female fetuses appear to reduce their claims on the mother when Phlda2 signalling rises, effectively shrinking their own growth to spare maternal reserves. Male fetuses, by contrast, hold their ground, continuing to extract resources even under adverse conditions. Such sex-specific strategies could reflect the different reproductive payoffs that sons and daughters offer under variable environmental conditions, with parent-of-origin imprinting serving as the molecular lever that mediates the negotiation.

The translational implications are hard to ignore. In human pregnancies, elevated placental PHLDA2 has repeatedly been associated with fetal growth restriction and low birthweight, yet these clinical studies have generally not accounted for the sex of the infant. If, as the mouse data suggest, the gene’s effects on growth are sex-specific, then pooling male and female pregnancies may have obscured important patterns and muddied the interpretation of biomarker studies. The Cardiff team argues that fetal sex deserves routine consideration in research on imprinted genes and pregnancy complications, from intrauterine growth restriction to the long-term metabolic and behavioural consequences of prenatal adversity. The work, funded by the Biotechnology and Biological Sciences Research Council, adds Phlda2 to a growing list of imprinted genes, alongside Peg3, whose disruption produces sex-dimorphic placental and offspring phenotypes, and it strengthens the broader hypothesis that the placenta is not merely a passive conduit for nutrients but an active, sexually differentiated endocrine organ that negotiates the terms of maternal investment on the fetus’s behalf.

Subject of Research: Sex-specific effects of loss-of-imprinting of the maternally expressed gene Phlda2 on placental endocrine development and fetal growth in mice

Article Title: Sex-specific consequences of loss-of-imprinting of the maternally expressed gene Pleckstrin Homology-Like Domain Family A Member 2 (Phlda2) on placental development and fetal growth

Article References: Chibnall, A., Harrison, D. J., Lysikova, E., Malinoshevska, M., Stoddart, A., Perry, I. A., Christofides, S., Isles, A. R., & John, R. M. (2026). Sex-specific consequences of loss-of-imprinting of the maternally expressed gene Pleckstrin Homology-Like Domain Family A Member 2 (Phlda2) on placental development and fetal growth. Biology of Sex Differences. https://doi.org/10.1186/s13293-026-00972-z

Image Credits: AI Generated

DOI: 10.1186/s13293-026-00972-z

Keywords: genomic imprinting, Phlda2, placenta, placental hormones, fetal growth restriction, sexual dimorphism, spongiotrophoblast, junctional zone, prenatal adversity, parent-of-origin effects, Biology of Sex Differences, Cardiff University

Central precocious puberty, or CPP, occurs when the hypothalamic-pituitary-gonadal axis is activated prematurely, leading to early breast development in girls and virilization in boys before the customary age. The condition matters clinically for more than cosmetic reasons: early activation of the axis accelerates skeletal maturation, can compromise final adult height, and may carry psychological and social consequences for children whose bodies mature years ahead of their peers. Over the past decade, loss-of-function mutations in MKRN3, an imprinted gene located in the Prader–Willi syndrome region of chromosome 15, have emerged as one of the most common genetic causes of familial CPP. Yet the same genomic neighborhood presents a paradox: when MKRN3 is deleted as part of the larger deletion that causes Prader–Willi syndrome, patients typically develop hypogonadism and delayed or incomplete puberty rather than precocious puberty. Because MKRN3 is paternally expressed and maternally imprinted, its loss through mutation removes an inhibitory brake on gonadotropin-releasing hormone secretion, hastening puberty, whereas the complex multi-gene deletion in Prader–Willi syndrome disrupts hypothalamic development in ways that blunt reproductive function.

The mechanistic basis for these opposing reproductive phenotypes has remained largely unclear. To address this, the team led by Yu-Yu Jin, Xiao Wang, Lin Yang, Jian Mu, and Fei-Hong Luo performed whole-exome sequencing on 98 Chinese children with central precocious puberty. They then carried out a systematic review of previously reported MKRN3 pathogenic and likely pathogenic variants to summarize genotype–phenotype correlations. Finally, they performed genome-wide DNA methylation profiling in CPP patients carrying the MKRN3 pathogenic variant and compared their methylation patterns with those of patients with Prader–Willi syndrome, patients with idiopathic central precocious puberty, and healthy controls. This three-pronged design allowed the investigators to move from variant discovery to clinical correlation to epigenetic characterization within a single cohort framework.

The sequencing effort identified a pathogenic frameshift variant, designated c.476dupC (p.Ala159fs*15), which introduces a duplication of a single cytosine base that shifts the reading frame and generates a premature stop codon. Notably, this is the first frameshift mutation reported within the inter-C3H1 hotspot region of MKRN3 in an Asian cohort, a finding that further confirms the functional significance of this segment of the protein. The MKRN3 protein carries multiple C3H-type zinc finger domains and a RING finger domain, and pathogenic variants have previously clustered in certain regions, making variant location an important clue to functional impact. The RING finger domain confers E3 ubiquitin ligase activity, meaning the protein tags other cellular proteins for degradation or modification, while the zinc finger domains mediate binding to RNA and protein targets. Frameshift variants that truncate the protein before these domains are complete are therefore expected to eliminate function almost entirely.

The genotype–phenotype analysis revealed a striking correlation between variant severity and clinical presentation. Patients carrying severe MKRN3 variants, such as frameshift or nonsense mutations predicted to truncate the protein, exhibited significantly earlier pubertal onset than those with missense mutations, beginning at a mean age of 5.80 years compared with 7.50 years (P = 0.029). The severity of the hormonal activation also differed: children with severe variants showed significantly higher luteinizing hormone peak levels during gonadotropin-releasing hormone stimulation testing, at 34.55 versus 11.00 IU/L (P = 0.047). These findings suggest that the degree of residual MKRN3 function, or the manner in which a truncated protein is produced and degraded, influences how vigorously the reproductive axis is disinhibited. In practical terms, the two-and-a-half-year difference in mean onset age between the variant classes is clinically meaningful, since earlier activation leaves a longer window of compromised growth potential and often requires more aggressive intervention with gonadotropin-releasing hormone agonist therapy to pause pubertal progression.

The most novel component of the study was the methylation analysis. DNA methylation, the addition of methyl groups to cytosine bases across the genome, is a key epigenetic mechanism that regulates gene expression without altering the underlying DNA sequence. Epigenetic regulation is known to be central to the timing of puberty: the reactivation of gonadotropin-releasing hormone secretion at the end of childhood is thought to depend on carefully orchestrated changes in chromatin state within hypothalamic neurons, and animal studies have shown that disrupting epigenetic machinery can shift pubertal timing substantially. MKRN3 itself has been implicated in epigenetic switching through its ubiquitination of MBD3, a component of chromatin-remodeling complexes. Given that MKRN3 sits in an imprinted genomic domain governed by methylation marks, the investigators asked whether MKRN3-associated CPP carries a distinct methylation signature.

Surprisingly, the analysis revealed no differences in methylation at the MKRN3 locus itself between the study groups. However, the comparison between MKRN3-CPP patients and Prader–Willi syndrome patients identified 18,609 differentially methylated positions across the genome, indicating that the two conditions, despite sharing the same chromosomal region, are epigenetically worlds apart. Key findings included pronounced hypermethylation of IGSF10 (a difference in methylation beta values of 0.37), ZC3H18 (0.27), SH3RF3 (0.36), and PTH1R (0.28) in the MKRN3-CPP group relative to PWS, alongside hypomethylation of MAGEL2 (−0.19) and PTPA (−0.23), where the delta-beta value represents the difference in DNA methylation beta values between the groups.

Several of these differentially methylated genes have plausible links to reproductive biology. IGSF10 is well established as a gene involved in the migration of gonadotropin-releasing hormone neurons during embryonic development, and mutations in it cause delayed puberty, making its epigenetic dysregulation particularly relevant to pubertal timing disorders. PTH1R, the parathyroid hormone 1 receptor, signals through the cAMP/protein kinase A pathway and is best known for its actions on bone. MAGEL2, which lies within the Prader–Willi syndrome critical region, is required for the production of secretory granules and neuropeptides in the hypothalamus, and its loss contributes to the impaired melanocortin pathway function characteristic of PWS. PTPA, a protein phosphatase 2A activator, has been shown to physically associate with the C-terminus of GPR54, the kisspeptin receptor that is a master gatekeeper of puberty, and has roles in osteoblast differentiation. SH3RF3 has been connected to the LIN28B pathway, which itself is among the genetic loci associated with age at menarche in large genome-wide association studies. Taken together, these targets trace a coherent map of the neuroendocrine and developmental circuits that determine when and how forcefully the reproductive axis awakens.

The authors propose that this pattern of differential methylation in downstream neuroendocrine pathways could potentially explain how divergent pubertal phenotypes arise in the setting of MKRN3 deficiency. In isolated MKRN3 mutations, the loss of the gene’s inhibitory action in kisspeptin-expressing neurons, together with its known role in modulating the stability and translation of GNRH1 messenger RNA through ubiquitination of poly(A)-binding proteins, removes the pubertal brake. In Prader–Willi syndrome, the methylation landscape of genes such as MAGEL2, a paternally expressed neighbor of MKRN3, is altered in the opposite direction, and the broader deletion disrupts neuropeptide production and hypothalamic circuitry, leading to insufficient rather than excessive gonadotropin secretion. The methylation data thus suggest that the clinical contrast between the two conditions may be inscribed in the epigenetic programming of shared downstream pathways rather than in MKRN3 itself. If confirmed, this would represent a conceptual shift: the direction of the pubertal phenotype would be determined not by the presence or absence of a single gene, but by the constellation of epigenetic states across the network it regulates.

The study has limitations worth noting. The methylation profiling was performed in peripheral blood samples, which may not fully reflect methylation states in the hypothalamic neurons that actually govern puberty, a common constraint in human neuroendocrine epigenetics. Blood-based methylation signatures can be confounded by differences in cell-type composition between patient groups, and tissue specificity remains a persistent challenge for the field. The cohort of MKRN3-mutant patients available for methylation comparison was necessarily small given the rarity of the condition, and the cross-sectional design cannot establish whether the methylation differences are causes or consequences of the divergent pubertal phenotypes. The researchers also note that the data were processed using beta-mixture quantile normalization to correct probe design bias in Illumina methylation arrays, and variant interpretation followed the American College of Medical Genetics and Genomics standards, but functional validation of the identified methylation changes will require further work, ideally in neuronal models or longitudinal cohorts.

Nevertheless, the implications are considerable. For clinicians, the genotype–phenotype correlation reinforces the value of molecular testing in children with central precocious puberty, particularly those with a family history or very early onset, and suggests that children with truncating MKRN3 variants may warrant particularly close attention to the pace of pubertal progression. Because MKRN3-related CPP is inherited in a pattern determined by the imprinting of the gene, molecular diagnosis also carries implications for genetic counseling of affected families, including the identification of relatives who carry the variant but may be asymptomatic. For researchers, the identification of an epigenetic signature distinguishing MKRN3-CPP from Prader–Willi syndrome opens a line of inquiry into how ubiquitin ligases and chromatin modifiers in the imprinted 15q11-q13 domain jointly sculpt the timing of human puberty. The work was supported by the National Natural Science Foundation of China and the Science and Technology Commission of Shanghai Municipality, and the data are available from the corresponding author on request.

More broadly, the study adds to a growing body of evidence that epigenetic marks can serve as interpretable intermediates between genetic lesions and complex developmental phenotypes. Just as methylation scores are being explored as predictors of metabolic disease risk, methylation profiling of pubertal disorders may eventually help stratify patients, refine prognosis, and illuminate therapeutic targets in the neuroendocrine circuitry that launches human reproduction. In an era when sequencing routinely uncovers rare variants of uncertain significance, studies that connect variant class, clinical severity, and epigenetic state provide exactly the kind of layered evidence needed to translate genomic findings into meaningful care for children whose puberty arrives, or fails to arrive, at the wrong time.